Mid-market employers don't have the prescription volume to negotiate specialty drug prices directly with manufacturers. And with median specialty drug list prices exceeding $370,000 in 2024, that gap isn't a minor inconvenience. It's a structural cost problem.
About 1 in 10 Americans lives with a rare or specialty condition. That's roughly 30 million people, according to reporting from Fierce Healthcare. At 300 employees, statistically you have several of them on your plan right now. You just don't know which claims are coming yet.
Key takeaways
The median specialty drug list price exceeded $370,000 in 2024. A single claim at that level can breach most mid-market stop-loss attachment points.
Employers project healthcare costs will rise 9.1% in 2026 before plan changes, and 8.0% even after mitigation, per the 2025 Best Practices in Healthcare Survey of 417 employers.
70% of employers are very concerned employees can't afford their medications, according to Kaiser Permanente's 2025 specialty drug guide.
PBM profit structures and rebate flows are opaque, making it nearly impossible for employers to know what a drug actually costs at net.
Individual employers without scale must look to collective purchasing models, carve-out PBMs, or stop-loss pooling to manage specialty exposure.
Medicare is negotiating prices for 15 drugs effective January 2028, but those savings don't automatically flow to commercial plans.
Why can't a mid-market employer negotiate specialty drug prices directly?
Manufacturers negotiate volume. A 300-person employer fills maybe one or two specialty scripts a year for a given drug. That's not a negotiation. That's a retail transaction.
Sub-340B pricing requires scale and program qualification that no individual mid-market employer will ever reach. Your PBM sits in the middle and negotiates on behalf of its entire book of business. But as the Washington University Law Review documented in 2025, PBM profit structures, rebates, and business models aren't fully transparent to anyone in the system.
Federal regulators have no oversight over manufacturer-PBM relationships. Most states have only minimal PBM oversight. You're paying somewhere in the pricing stack without knowing where.
What does the actual cost trajectory look like for employers?
The 2025 Best Practices in Healthcare Survey, covering 417 employers and five million employees, put cost projections in sharp relief. Before any plan changes, healthcare costs are expected to climb 9.1% in 2026, up from 8.1% in 2025 and 7.0% in 2024.
After planned program adjustments, the numbers drop but don't disappear. Employers still project 8.0% growth in 2026, 7.0% in 2025, and 6.0% in 2024. Mitigation strategies are working at the margin, not at the source.
Before you keep reading
Get the next one in your inbox.
Analysis like this, every other Wednesday. Written for the person who signs the renewal.
Subscribe and get the PBM Renegotiation Checklist. Free PDF.
Every other Wednesday. Unsubscribe anytime. We may show your company’s logo on our homepage. Privacy
Group medical captives and stop-loss purchasing pools let smaller employers aggregate claims risk. That creates two things: better stop-loss pricing and, in some structures, meaningful collective purchasing power. The mechanics are covered at Group Medical Captives: How Employers Pool Stop-Loss Risk.
A third option is formulary design. Biosimilar substitution, step therapy protocols, and site-of-care management don't replace volume negotiation, but they reduce avoidable spend. Your PBM may actually be working against biosimilar adoption, a problem documented at Biosimilar Adoption Is Stalling. Your PBM Is Probably the Reason.
Will Medicare drug negotiations help commercial employers?
KFF's analysis of Medicare drug price negotiation shows Medicare's first 15 negotiated drugs covered $27 billion in gross spending between November 2024 and October 2025, serving 1.8 million beneficiaries. A second round of 15 drugs covering type 2 diabetes, HIV, asthma, arthritis, psoriasis, and Crohn's disease takes effect January 1, 2028. That's meaningful progress inside Medicare.
Those negotiated prices don't automatically transfer to commercial plans. Manufacturers set separate commercial pricing, and your PBM negotiates against that. Medicare wins don't become employer wins by default.
The indirect effect may come through market pressure over time. But employers shopping for 2026 renewals won't see 2028 Medicare prices in their formulary today. Plan accordingly.
Frequently asked questions
What is the median specialty drug list price in 2024?
The median specialty drug list price exceeded $370,000 in 2024. A single claim at that level can breach most mid-market stop-loss attachment points and move a renewal on its own.
Can a small or mid-market employer negotiate directly with drug manufacturers?
No. Manufacturers negotiate based on prescription volume. A 300-person employer fills too few specialty scripts for any given drug to warrant a direct negotiation. That's functionally a retail transaction.
What is a specialty drug carve-out PBM?
A carve-out PBM focuses exclusively on high-cost or specialty drug categories. Some offer pass-through contract terms, meaning rebates flow back to the employer rather than staying with the PBM. That's a structural difference from traditional PBM arrangements.
Will Medicare's negotiated drug prices apply to employer health plans?
Not automatically. Medicare negotiates prices for its own program. Manufacturers set separate commercial pricing, and employer plans negotiate through their PBM against that commercial baseline. Medicare wins don't transfer to employer plans by default.
How many employees does a mid-market employer typically have on a specialty drug?
About 1 in 10 Americans lives with a rare or specialty condition. At 300 employees, statistical probability means several are already on your plan. The claims just haven't surfaced in your data yet.
